Navigation Links
La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial

Data Support Ability of Higher Doses to Further Reduce Antibodies to Double-Stranded DNA

SAN DIEGO, March 08, 2007 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced positive interim antibody results from its ongoing double-blind, placebo-controlled randomized Phase 3 trial of Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE"). Analyses of interim antibody data indicate that patients treated with 900 mg or 300 mg per week doses of Riquent had greater reductions in antibodies to double-stranded DNA (dsDNA) than patients treated with 100 mg per week or placebo. The results showed a significant dose response when comparing all Riquent-treated patients to placebo-treated patients (p < 0.0001), and each Riquent dose group to the placebo dose group (p < 0.0015 for 100 mg, p < 0.0001 for 300 mg and 900 mg).

"We are very excited by these results. The higher the dose, the greater the reduction in antibodies to dsDNA, and the relative magnitude of these reductions is greater than we have seen in previous studies, which used lower doses of Riquent. Higher doses also appear to result in a larger percentage of patients having greater and more consistent antibody reductions over time," said Deirdre Y. Gillespie, M.D., President and CEO of La Jolla Pharmaceutical Company. "In addition, preliminary assessment of the data indicates that Riquent is being as well tolerated at all doses in the ongoing Phase 3 study as in our previous studies. We believe that the greater reductions in antibodies to dsDNA observed with these higher doses of Riquent imply a greater probability of obtaining positive clinical results from the Phase 3 trial."

"These data definitely show an increased biological effect. This will improve the likelihood of detecting clinical effects of the treatment," said Joan Merrill, M.D. of the Oklahoma Medical Research Foundation. "
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:12/22/2014)... Dec, 22, 2014  Eiger BioPharmaceuticals Incorporated announced ... of lonafarnib in patients with chronic hepatitis delta ... the National Institutes of Health (NIH) Clinical Center ... double-blinded, randomized, placebo-controlled, dose ascending study evaluated two ... 200 mg twice daily for 28 days.  "This ...
(Date:12/22/2014)... -- TWi Biotechnology, Inc., today announced that it ... Biotechnology,s lead drug candidate, from The State Intellectual ... for patent application numbered 201180018154.8.  This patent includes ... for treatment of type II diabetes.  The patent ... for type II diabetes, and provides a protection ...
(Date:12/19/2014)... 19, 2014  Newport Corporation (NASDAQ: ... has joined the company,s Board of Directors.  Dr. ... a director of Evans Analytical Group, a leading ... analytical services to companies in a wide range ... Evans Analytical Group, Dr. Kadia spent nine years ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... Aug. 30 Laerdal Medical has been at ... the company launched its famous Resusci Anne in ... to bear as it launches its latest SimMan ... http://photos.prnewswire.com/prnh/20100830/NY56743 ) (Photo: http://www.newscom.com/cgi-bin/prnh/20100830/NY56743 ...
... To Attend ROTH Fall Conference at Maui, Hawaii From September 1 -... -- CHENGDU, China, Aug. ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Medicine Technology:Laerdal Introduces SimMan Essential 2Laerdal Introduces SimMan Essential 3Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6 2Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6 3Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6 4Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6 5Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6 6
(Date:12/22/2014)... (PRWEB) December 22, 2014 Fad diets ... changed. The reason why most fad diets have hung ... The problem with fad diets is that, as the body ... the dieter uncertain of how to reset the metabolism to ... reason, Diet Doc developed their all-inclusive diet plans ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The founders ... BLS and ACLS online certification provider, are proud to ... . The updated site now features a more user-friendly ... ever to use. , As a company spokesperson ... is now consolidated into a single page during the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... current Ebola virus epidemic are receiving further ... government agencies, nongovernmental organizations (NGOs) and other ... ongoing, healthcare workers, emergency responders, patients and ... such as the CmTP MediDefense system ...
(Date:12/22/2014)... Physicians in China are most eagerly ... of non-Hodgkin’s lymphoma (NHL), according to a new report ... consulting firm. MabThera is the only biologic available to ... form of NHL. , According to Kantar Health’s report, ... of NHL in China has been growing and is ...
(Date:12/22/2014)... OH (PRWEB) December 22, 2014 Explorys, ... three additions to its leadership team: Greg Yarrington as ... of Engineering, and Patrick Wells as Vice President of ... to add 80 new jobs in 2015 to support ... expansion of its platform-as-a-service offerings, and growth of its ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:ACLS Online Certification Website ACLS-PALS-BLS.com Now Features a New and User-Friendly Layout 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3
... at Wake Forest University Baptist Medical Center (WFUBMC) have discovered ... breast cancer. For the first time, a peptide found in ... of human breast tumors in mice, according to a study ... Patricia E. Gallagher, Ph.D., and E. Ann Tallant, Ph.D., scientists ...
... Hydrocephalus in Ugandan children and other developing countries is ... by previous bacterial infection, according to an international team ... believe that the best approach to this problem is ... grand medical mystery," said Steven Schiff, the Brush Chair ...
... , THURSDAY, Dec. 30 (HealthDay News) -- Certain ... a new study finds. Because of increasing urbanization, ... more than ever before. For example, foxes, raccoons and ... mice, rats, birds and other prey. For this ...
... , , , , , ... , AUDIO: Its not news ... Click here for more information. , ... , , , , , ...
... -- Researchers report that they,ve gained insight into the workings ... in how the body stores fat to protect against future ... be linked to both insulin sensitivity and the survival of ... all these different phenomena," Dr. Philipp Scherer, a professor of ...
... Reporter , THURSDAY, Dec. 29 (HealthDay News) -- As fears ... gripped much of the United States the past two winters, George ... As vice president of human resources for a Fort Lauderdale commercial ... and protect not only the company,s employees but also the tenants ...
Cached Medicine News:Health News:Peptide delivers 1-2 punch to breast cancer in pre-clinical study 2Health News:Infant hydrocephalus, seasonal and linked to farm animals in Uganda 2Health News:Infant hydrocephalus, seasonal and linked to farm animals in Uganda 3Health News:Infant hydrocephalus, seasonal and linked to farm animals in Uganda 4Health News:Consistent exercise associated with lower risk of colon cancer death 2Health News:Consistent exercise associated with lower risk of colon cancer death 3Health News:Research Sheds Light on 'Starvation Hormone' 2Health News:How One Company Fought the Flu 2
... a large body for increased stability ... centimeters center-to-center) to resist the wear ... indicators are molded into the body. ... bar electrode styles. Shielded bar electrodes ...
... Cadwell's custom bars have a ... solid, machined contacts (spaced 3 centimeters ... tear of repeated cleaning. Polarity indicators ... convenient, snap-on handle fits our bar ...
The Surgifresh mini has the same rugged construction as the Plume-inator. It is the ideal size for operating room, clinic and office settings. This unit includes a filter test button, hospital grade ...
... Evolutionary refractive lens technology for ... safety and efficacy, demonstrates quality of ... contact lens correction. The lens is ... and is now available for the ...
Medicine Products: